Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunologic Targeting of ESR1 in Metastatic Breast Cancer
NCT06691035Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DC1 in breast cancer, sponsored by Moffitt Cancer Center. Primary endpoints: Rate of Successful Completion up to 2 years, Occurrence Rate up to 2 years and 1 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
DC1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06691035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691035.